Key Players Engaged in Organ on a Chip Market
Organ-on-a-chip technology is still in its early stages of development, and the pharmaceutical sector is actively testing and evaluating it. OOC makers must be able to demonstrate and give similar quality data of OOCs with existing animal studies for the aim of safety evaluation to move on from animal research. Based on the data, the food and drug administration can determine whether such a shift is feasible. The technology is still in its early stages, and there isn't enough proof to back up its real-time applications. In this article, we are going to discuss the leading market players that are engaged in the Organ on a Chip market.
TissUse is a German start-up founded in 2010 at Berlin's Technische University. The business has created a multi-organ-on-chip with four organs on the same chip, as well as a variety of organs-on-chips. It is presently working on a new human-on-chip with ten organs, which would be a huge breakthrough, especially given how difficult it may be to connect that many organs.
A human lung-on-a-chip model was produced by AlveoliX. This model can simulate the biophysical milieu of the human lung's air-blood barrier, including mechanical stress from inspiration and expiration, and is intended to accurately predict the effects of respiratory medication candidates in people, reducing the number of clinical trials.
Nortis Bio was founded in 2012 at the University of Washington in the United States. Since then, the firm has focused on developing organs-on-chips, particularly kidneys-on-chip. Their objective is to create a new generation of in vitro systems that will enhance research on novel medicines while also reducing development costs and time.
BEOnChip creates innovative cell culture equipment in an attempt to make the cell environment as biomimetic feasible. That is, they must recreate the same environment in the laboratory as they would in the human body. Drug testing would become more practical, realistic, as a result of this technology, and the time and expense of developing new treatments to treat ailments like cancer or heart attacks would be reduced.
Microfluidic cell culture tools for research laboratories have been created by Cherry Biotech SAS. Its current focus is on creating a new generation of cell environment management that is tailored to organs-on-chip.
The demand for customized medicine and the wide range of applications for organ-on-chip technology outside of the pharmaceutical sector are two important reasons driving market expansion. The intricacy of organ-on-chip models, on the other hand, may hamper market growth throughout the forecast period.